<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2859">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04801836</url>
  </required_header>
  <id_info>
    <org_study_id>MIT-Co001-C101</org_study_id>
    <secondary_id>2020-003403-33</secondary_id>
    <nct_id>NCT04801836</nct_id>
  </id_info>
  <brief_title>Estetrol (E4) for the Treatment of Patients With Confirmed SARS-COV-2 Infection</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Trial to Determine the Safety and Efficacy of Estetrol (E4) for the Treatment of Patients With Confirmed SARS-COV-2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NEURALIS s.a.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NEURALIS s.a.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess if E4 is safe and if it could help to protect participants from the&#xD;
      more severe symptoms of COVID 19. It has been reported in several research studies that men&#xD;
      are almost twice as likely to progress to severe COVID 19 disease and die than women. Some&#xD;
      researchers have suggested this is due to the activity of estrogen which is produced by the&#xD;
      ovaries in pre-menopausal women. Men and post-menopausal women produce very low levels of&#xD;
      estrogen. This study will look whether E4, a natural estrogen, can help men and&#xD;
      post-menopausal women that are hospitalized with COVID 19 infection but for whom help&#xD;
      breathing is not yet needed. The purpose of this study is to see if E4 can reduce the risk of&#xD;
      progression to more severe disease.&quot;&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants who have recovered at Day 28</measure>
    <time_frame>At Day 28</time_frame>
    <description>Participants have recovered if they have reached a score ≤3 on the World Health Organization (WHO) (0-10) scale.&#xD;
The WHO Ordinal Scale for Clinical Improvement is as follows: 0) uninfected; 1) ambulatory, asymptomatic; 2) ambulatory, symptomatic, independent; 3) ambulatory, symptomatic, assistance needed; 4) hospitalized, no oxygen therapy; 5) hospitalized, oxygen by mask or nasal prongs; 6) hospitalized, non-invasive ventilation or high-flow oxygen; 7) hospitalized, intubation and mechanical ventilation, pO2/FiO2 ≥150 or SpO2/FiO2 ≥200; 8) hospitalized, mechanical ventilation pO2/FiO2 &lt;150 (SpO2/FiO2 &lt;200) or vasopressin; 9) hospitalized, mechanical ventilation, pO2/FiO2 &lt;150 and vasopressin, dialysis, or extracorporeal membrane oxygenation (ECMO); 10) dead.&#xD;
[FiO2, fraction of inspired oxygen; pO2, partial pressure of oxygen; SpO2, oxygen saturation]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants reaching a score of ≥6 on the WHO (0-10) scale at Day 28</measure>
    <time_frame>At Day 28</time_frame>
    <description>The WHO Ordinal Scale for Clinical Improvement is as follows: 0) uninfected; 1) ambulatory, asymptomatic; 2) ambulatory, symptomatic, independent; 3) ambulatory, symptomatic, assistance needed; 4) hospitalized, no oxygen therapy; 5) hospitalized, oxygen by mask or nasal prongs; 6) hospitalized, non-invasive ventilation or high-flow oxygen; 7) hospitalized, intubation and mechanical ventilation, pO2/FiO2 ≥150 or SpO2/FiO2 ≥200; 8) hospitalized, mechanical ventilation pO2/FiO2 &lt;150 (SpO2/FiO2 &lt;200) or vasopressin; 9) hospitalized, mechanical ventilation, pO2/FiO2 &lt;150 and vasopressin, dialysis, or extracorporeal membrane oxygenation (ECMO); 10) dead.&#xD;
[FiO2, fraction of inspired oxygen; pO2, partial pressure of oxygen; SpO2, oxygen saturation]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recovery</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Participants have recovered if they have reached a score ≤3 on the World Health Organization (WHO) (0-10) scale.&#xD;
The WHO Ordinal Scale for Clinical Improvement is as follows: 0) uninfected; 1) ambulatory, asymptomatic; 2) ambulatory, symptomatic, independent; 3) ambulatory, symptomatic, assistance needed; 4) hospitalized, no oxygen therapy; 5) hospitalized, oxygen by mask or nasal prongs; 6) hospitalized, non-invasive ventilation or high-flow oxygen; 7) hospitalized, intubation and mechanical ventilation, pO2/FiO2 ≥150 or SpO2/FiO2 ≥200; 8) hospitalized, mechanical ventilation pO2/FiO2 &lt;150 (SpO2/FiO2 &lt;200) or vasopressin; 9) hospitalized, mechanical ventilation, pO2/FiO2 &lt;150 and vasopressin, dialysis, or extracorporeal membrane oxygenation (ECMO); 10) dead.&#xD;
[FiO2, fraction of inspired oxygen; pO2, partial pressure of oxygen; SpO2, oxygen saturation]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load</measure>
    <time_frame>At Days 1, 3, 7, and 14, and end of treatment visit (on Day 23 or within 48 hours of the last dose of study drug if treatment is stopped prior to Day 21)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse events (AEs), Serious adverse events (SAEs), Adverse events of special interest (AESIs) and Laboratory abnormalities as a measure of safety</measure>
    <time_frame>Up to end of study (on Day 28 (±2 days) or 7 days (±2 days) after the last dose of study drug if treatment is stopped prior to Day 21)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 15 mg E4 orally once daily for 21 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive matching placebo orally once daily for 21 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estetrol monohydrate 15 mg</intervention_name>
    <description>One Estetrol monohydrate (E4) 15 mg tablet once per day</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>E4 15 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One placebo tablet once per day</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Postmenopausal women who have not used hormone replacement therapy (including oral,&#xD;
             transdermal, topical, or vaginal preparations) within 1 year prior to study start.&#xD;
             Menopause is defined as women who have at least 12 months of spontaneous amenorrhea&#xD;
             without another medical cause.&#xD;
&#xD;
             OR Men ≥18 years of age who are willing to use adequate contraception from Screening&#xD;
             until 4 weeks after the last dose of study treatment.&#xD;
&#xD;
          2. Patients with SARS-CoV-2 infection confirmed by a nationally accepted RT-PCR assay and&#xD;
             moderate COVID-19.&#xD;
&#xD;
             Patients with a strong clinical suspicion of moderate COVID-19 and a positive&#xD;
             point-of-care test for viral infection can also be entered while the result of a&#xD;
             nationally accepted RT-PCR assay is awaited; if the RT-PCR assay result is negative,&#xD;
             the treatment must be stopped and the patient must be discontinued from the study.&#xD;
&#xD;
             The definition of moderate COVID-19 is:&#xD;
&#xD;
             i. Positive testing by a standard nationally accepted RT-PCR assay. ii. Symptoms of&#xD;
             moderate illness with COVID-19, which could include any symptom of mild illness&#xD;
             (including fever, cough, anosmia, dysgeusia, sore throat, malaise, headache, muscle&#xD;
             pain, gastrointestinal symptoms) or shortness of breath with exertion.&#xD;
&#xD;
             iii. Clinical signs suggestive of moderate illness with COVID-19, such as respiratory&#xD;
             rate ≥20 breaths per minute, heart rate ≥90 beats per minute.&#xD;
&#xD;
             iv. No clinical signs indicative of severe or critical illness (i.e. need for&#xD;
             ventilation or intensive care unit (ICU) admission).&#xD;
&#xD;
          3. Hospitalized.&#xD;
&#xD;
          4. Clinical Frailty Score ≤5.&#xD;
&#xD;
             The Clinical Frailty Scale is a nine-point global frailty scale (ranging from 1: &quot;very&#xD;
             fit&quot; to 9: &quot;terminally ill&quot;) based on clinical evaluation in the domains of mobility,&#xD;
             energy, physical activity, and function. People scoring at 5: &quot;mildly frail&quot; often&#xD;
             have more evident slowing and need help in high order Instrumental Activities of Daily&#xD;
             Living (IADLs) (finances, transportation, heavy housework, medications). Typically,&#xD;
             mild frailty progressively impairs shopping and walking outside alone, meal&#xD;
             preparation and housework.&#xD;
&#xD;
          5. WHO Ordinal Scale for Clinical Improvement score of 4 or 5.&#xD;
&#xD;
          6. Able to provide informed consent.&#xD;
&#xD;
          7. Able to comply with the study procedures as defined in this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Males currently receiving estrogen-based hormonal therapy.&#xD;
&#xD;
          2. Current participation in another interventional clinical trial.&#xD;
&#xD;
          3. Ventilated and/or in ICU.&#xD;
&#xD;
          4. Any unexplained abnormal bleeding including, but not limited to, vaginal bleeding.&#xD;
&#xD;
          5. Diagnosed protein C, protein S or antithrombin III deficiency or any other known&#xD;
             inherited or acquired thrombophilic abnormalities (e.g. hyperhomocysteinemia,&#xD;
             anti-phospholipid antibodies).&#xD;
&#xD;
          6. Renal impairment (glomerular filtration rate [GFR] &lt;30 mL/min/1.73 m²).&#xD;
&#xD;
          7. Presence or history of severe liver disease or liver cancer (non-malignant or&#xD;
             malignant).&#xD;
&#xD;
          8. Presence or history (including suspected diagnosis) of breast cancer.&#xD;
&#xD;
          9. Presence or history (including suspected diagnosis) of estrogen-sensitive tumors (e.g.&#xD;
             endometrial cancer).&#xD;
&#xD;
         10. Patients with endometrial hyperplasia.&#xD;
&#xD;
         11. Patients with severe hypoxemia at risk of endotracheal intubation.&#xD;
&#xD;
         12. Immunocompromised patients&#xD;
&#xD;
         13. History of stroke, acute coronary syndromes, or angina pectoris.&#xD;
&#xD;
         14. Presence, history, or patients at risk of development of arterial or venous&#xD;
             thrombosis/thrombembolia (including deep vein thrombosis and pulmonary emboli).&#xD;
&#xD;
         15. Patients with any condition, including findings in the patients' medical history or in&#xD;
             the screening study assessments that in the opinion of the Investigator, constitute a&#xD;
             risk or a contraindication for the participation of the patient into the study or that&#xD;
             could interfere with the study objectives, conduct or evaluation, including patients&#xD;
             with suspected genital cancer or suspected breast cancer.&#xD;
&#xD;
         16. Use of zanamivir or oseltamivir within 1 week prior to randomization.&#xD;
&#xD;
         17. Vaccinations within 30 days of Screening.&#xD;
&#xD;
         18. Patients who have received prior investigational or off-label agents for COVID-19.&#xD;
             (Note: use of antivirals and corticosteroids is allowed if part of Standard of Care).&#xD;
&#xD;
         19. Using methyldopa or clonidine containing antihypertensive medication.&#xD;
&#xD;
         20. Hypersensitivity to the active substance of the study drug or any other components of&#xD;
             the study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ERASME Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maya Hites</last_name>
      <phone>+32 2 555 57 79</phone>
      <email>maya.hites@erasme.ulb.ac.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHR Citadelle</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine Altdorfer</last_name>
      <phone>+32 4 321 55 42</phone>
      <email>Antoine.Altdorfer@chrcitadelle.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Koranyi National Institute of Pulmonology</name>
      <address>
        <city>Budapest</city>
        <zip>1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Hejja</last_name>
      <email>maria.hejja@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pecs Medical Center</name>
      <address>
        <city>Pécs</city>
        <zip>7623</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zoltan Peterfi</last_name>
      <phone>+36 20 9759845</phone>
      <email>peterfi.zoltan@pte.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Szeged Medical Center</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edit Hajdu</last_name>
      <phone>+36 62 545186</phone>
      <email>office.in1st@med.u-szeged.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szent Borbala Korhaz</name>
      <address>
        <city>Tatabánya</city>
        <zip>2800</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Csaba Bocskei</last_name>
      <email>csbocskei5@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej Oddział Kardiologiczny Pododdział Kardiologii Zachowawczej</name>
      <address>
        <city>Biała Podlaska</city>
        <zip>21-500</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Centkowski</last_name>
      <phone>+48 603 314 074</phone>
      <email>pcentek@wp.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zespół Opieki Zdrowotnej w Bolesławcu Oddział Chorób Wewnętrznych</name>
      <address>
        <city>Boleslawiec</city>
        <zip>59-700</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justyna Staszak-Trzeciak</last_name>
      <phone>+48 504 055 865</phone>
      <email>justynatrzeciak@interia.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arion Med. Sp z o.o. Zespół Opieki Zdrowotnej w Gostyninie Oddział Chorób Wewnętrznych</name>
      <address>
        <city>Gorzewo</city>
        <zip>09-500</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Małgorzata Andrzejczak</last_name>
      <phone>+48 668 008 207</phone>
      <email>malgorzata.andrzejczak@biomedical-centers.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zakad Opieki Zdrowotnej w Pulawach Oddział Obserwacyjno-Zakaźny</name>
      <address>
        <city>Puławy</city>
        <zip>24-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tomasz Piekoś</last_name>
      <phone>+48 81 888 63 63</phone>
      <email>tomasz.piekos@komed-ck.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zespół Zakładów Opieki Zdrowotnej w Staszowie Oddział Chorób Wewnętrznych</name>
      <address>
        <city>Staszów</city>
        <zip>28-200</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrzej Janik</last_name>
      <phone>+48 533 691 047</phone>
      <email>andrzej.janik@komed-ck.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wielospecjalistycznego Szpitala im. J. Strusia z Zakładem Opiekuńczo - Leczniczym SP ZOZ Oddział Chorób Wewnętrznych</name>
      <address>
        <city>Szczecin</city>
        <zip>71-455</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcin Żytkiewicz</last_name>
      <phone>+48 604120069</phone>
      <email>mzytkiewicz@szpital-strusia.poznan.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Matki Bożej Nieustającej Pomocy w Wołominie Oddział Chorób Wewnętrznych</name>
      <address>
        <city>Wołomin</city>
        <zip>05-200</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarzyna Kamińska</last_name>
      <phone>+48 601 261 626</phone>
      <email>katarzyna.kaminska@biomedical-centers.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny im. J. Gromkowskiego I Oddział Chorób Zakaźnych</name>
      <address>
        <city>Wrocław</city>
        <zip>51-149</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Pazgan-Simon</last_name>
      <phone>+48 693 133 342</phone>
      <email>monika.pazgan.simon@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #15 n.a. Filatov</name>
      <address>
        <city>Moscow</city>
        <zip>111539</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>State budgetary healthcare institution of Moscow &quot;City Clinical Hospital No 52 of the Department of Healhcare of Moscow&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>123182</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daria Fomina</last_name>
      <phone>+7 916 597 18 06‬</phone>
      <email>daria_fomina@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution &quot;Clinical Infectious Disease Hospital No. 1 of the Moscow City Health Department&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dmitry Bystritsky</last_name>
      <phone>+7 916 777 2411</phone>
      <email>bistritskiyda@ikb1.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg state budgetary healthcare institution &quot;Clinical infectious hospital n.a. S.P. Botkin&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vladimir Musatov</last_name>
      <phone>+7 911 211 0112</phone>
      <email>doctormusatov@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>City Hospital #15</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>198205</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Boris Goloshchekin</last_name>
      <phone>+7 911 912 3956</phone>
      <email>bgoloschekin@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg state budgetary healthcare institution &quot;Pokrovskaya City Hospital&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>199106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Vishnevsky</last_name>
      <phone>+7 921 992 3464</phone>
      <email>alvishn@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg state budgetary healthcare institution &quot;Alexandrovskaya City Hospital&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>193312</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roman Bogdanov</last_name>
      <phone>+7 905 283 0528</phone>
      <email>bogdanov812@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg state budgetary healthcare institution &quot;City hospital No 40 of resort region&quot;</name>
      <address>
        <city>Sestroretsk</city>
        <zip>197706</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alina Agafina</last_name>
      <phone>+7 (921) 583-78-08</phone>
      <email>a.agafina@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Budgetary healthcare institution of Voronezh Region &quot;Voronezh regional clinical hospital&quot;</name>
      <address>
        <city>Voronezh</city>
        <zip>394066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>State budgetary healthcare institution of the Yaroslavl Region &quot;Yaroslavl regional clinical hospital of the war veterans - international center for health problems of aged people &quot;Healthy longevity&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Mozheiko</last_name>
      <phone>+7 905 639 1139</phone>
      <email>mmozheiko@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>State budgetary healthcare institution of Moscow Region &quot;Zhukovskaya City Clinical Hospital&quot;</name>
      <address>
        <city>Zhukovskiy</city>
        <zip>140160</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Urinsky</last_name>
      <phone>+7 916 338 3186</phone>
      <email>alexandr4doc@mail.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 12, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARs-CoV-2 infection</keyword>
  <keyword>COVID 19 infection</keyword>
  <keyword>Estetrol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

